SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering
committee of ENDO 2015 has selected the abstract of their recently
completed clinical study of NBI-77860 in classic congenital adrenal
hyperplasia for an oral presentation on the initial day of the
Endocrine Society's 97th Annual Meeting. ENDO is the
world's largest endocrinology meeting drawing over 10,000 experts
from around the world. The ENDO 2015 meeting will be held in
San Diego from March 5-8, 2015.
"We are pleased to have been selected to hold an oral
presentation at the annual meeting of the Endocrine Society and to
share the clinical data of NBI-77860 in classic congenital adrenal
hyperplasia with the broader scientific community," said
Chris O'Brien, M.D., Chief Medical
Officer at Neurocrine. "Congenital adrenal hyperplasia is a disease
with a significant unmet medical need and NBI-77860 may potentially
make an important difference in patients' lives. The ENDO annual
meeting brings together the world's thought leaders in
endocrinology to discuss the latest advances in the field and we
look forward to discussing our clinical results at this
meeting."
The oral presentation of the results from the initial clinical
study of NBI-77860 for the treatment of classic congenital adrenal
hyperplasia will occur at the 97th Annual Meeting of the
Endocrine Society on Thursday, March 5,
2015 from 11:30 am to 1:00 pm
(PST). The session is entitled "HPA Axis and Adrenal:
Receptors to Clinical Impact."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial
rights to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with Neurocrine's business and finances in general, and Company
overall. In addition, the Company faces risks and uncertainties
with respect to the Company's R & D pipeline including risk
that the Company's clinical candidates will not be found to be safe
and effective; and the other risks described in the Company's
report on Form 10-K for the year ended December 31, 2013 and on Form 10-Q for each of
the quarters ended March 31, 2014,
June 30, 2014 and September 30, 2014. Neurocrine undertakes no
obligation to update the statements contained in this press release
after the date hereof.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-oral-presentation-of-nbi-77860-clinical-trial-data-in-classic-congenital-adrenal-hyperplasia-at-endo-2015-300022371.html
SOURCE Neurocrine Biosciences, Inc.